Cytori Granted Foundational Japanese Patent for its Celution® System Technology
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Cytori Therapeutics has been issued Patent No. 4653952 (the '952 patent) from the Japan Patent Office covering devices for extracting and concentrating the stem and regenerative cells which naturally exist within adipose tissue. Specifically, the patent describes the underlying technology for Cytori's Celution® System family of devices including the Celution® 800 series of devices and the next-generation Celution® One series of devices, as well as the StemSource® laboratory equipment.
This '952 patent is the Company's first to issue in Japan, creating a significant barrier-to-entry through at least 2022 in the second largest medical market in the world and a country where Cytori has ongoing strategic and commercial activities.
Cytori formed a Joint Venture with Olympus Corporation in 2005 to develop and manufacture future generation devices based on Cytori's Celution® System.
With claims similar to the core 7,390,484 patent in the United States, this patent will serve as the foundational patent in Japan, around which Cytori has applied for additional patents covering specific applications for the cells.
Cytori now has 30 issued patents worldwide, including 11 issued patents in the United States as well as issued patents in Korea, China, Singapore and more than 100 additional pending applications worldwide. Our existing patents cover the Company's core device technology which automates the process of extracting a mixed population of adipose-derived stem and regenerative cells by way of a closed, bedside system, as well as methods and uses of these cells for a variety of clinical applications.
This '952 patent is the Company's first to issue in Japan, creating a significant barrier-to-entry through at least 2022 in the second largest medical market in the world and a country where Cytori has ongoing strategic and commercial activities.
Cytori formed a Joint Venture with Olympus Corporation in 2005 to develop and manufacture future generation devices based on Cytori's Celution® System.
With claims similar to the core 7,390,484 patent in the United States, this patent will serve as the foundational patent in Japan, around which Cytori has applied for additional patents covering specific applications for the cells.
Cytori now has 30 issued patents worldwide, including 11 issued patents in the United States as well as issued patents in Korea, China, Singapore and more than 100 additional pending applications worldwide. Our existing patents cover the Company's core device technology which automates the process of extracting a mixed population of adipose-derived stem and regenerative cells by way of a closed, bedside system, as well as methods and uses of these cells for a variety of clinical applications.
